JASPER THERAPEUTICS, INC. Operating Income
JASPER THERAPEUTICS, INC. (JSPR) reported Operating Income of -$9.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$9.21M.
- JASPER THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$10.95M.
- JASPER THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$15.84M.
- JASPER THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$19.17M.
- JASPER THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$83.88M.
- JASPER THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$76.24M.
- JASPER THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$68.86M.
- JASPER THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$51.20M.
| Period end | Operating Income (Loss) | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 5 month | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.21M 10-Q · filed 2026-08-14 | -$20.16M 10-Q · filed 2026-08-14 | -$36.00M derived: sum of 3 quarters · filed 2026-08-14 | -$55.16M derived: sum of 4 quarters · filed 2026-08-14 | |||||||
| 2026-03-31 | -$10.95M 10-Q · filed 2026-05-14 | -$26.79M derived: sum of 2 quarters · filed 2026-05-14 | -$45.96M derived: sum of 3 quarters · filed 2026-05-14 | -$73.03M derived: sum of 4 quarters · filed 2026-08-14 | |||||||
| 2025-12-31 | -$15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$35.01M derived: sum of 2 quarters · filed 2026-03-30 | -$62.08M derived: sum of 3 quarters · filed 2026-08-14 | -$83.88M 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | -$19.17M 10-Q · filed 2025-11-10 | -$46.24M derived: sum of 2 quarters · filed 2026-08-14 | -$68.04M 10-Q · filed 2025-11-10 | -$93.33M derived: sum of 4 quarters · filed 2026-08-14 | |||||||
| 2025-06-30 | -$27.08M 10-Q · filed 2026-08-14 | -$48.88M 10-Q · filed 2026-08-14 | -$74.16M derived: sum of 3 quarters · filed 2026-08-14 | -$94.05M derived: sum of 4 quarters · filed 2026-08-14 | |||||||
| 2025-03-31 | -$21.80M 10-Q · filed 2026-05-14 | -$47.09M derived: sum of 2 quarters · filed 2026-05-14 | -$66.98M derived: sum of 3 quarters · filed 2026-05-14 | -$82.97M derived: sum of 4 quarters · filed 2026-05-14 | |||||||
| 2024-12-31 | -$25.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$45.17M derived: sum of 2 quarters · filed 2026-03-30 | -$61.17M derived: sum of 3 quarters · filed 2026-03-30 | -$76.24M 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | -$19.89M 10-Q · filed 2025-11-10 | -$35.88M derived: sum of 2 quarters · filed 2025-11-10 | -$50.95M 10-Q · filed 2025-11-10 | -$68.68M derived: sum of 4 quarters · filed 2025-11-10 | |||||||
| 2024-06-30 | -$15.99M 10-Q · filed 2025-08-13 | -$31.07M 10-Q · filed 2025-08-13 | -$48.79M derived: sum of 3 quarters · filed 2025-08-13 | -$68.15M derived: sum of 4 quarters · filed 2025-08-13 | |||||||
| 2024-03-31 | -$15.07M 10-Q · filed 2025-05-12 | -$32.80M derived: sum of 2 quarters · filed 2025-05-12 | -$52.16M derived: sum of 3 quarters · filed 2025-05-12 | -$69.99M derived: sum of 4 quarters · filed 2025-05-12 | |||||||
| 2023-12-31 | -$17.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$37.09M derived: sum of 2 quarters · filed 2025-02-28 | -$54.91M derived: sum of 3 quarters · filed 2025-02-28 | -$68.86M 10-K · filed 2025-02-28 | |||||||
| 2023-09-30 | -$19.36M 10-Q · filed 2024-11-07 | -$37.19M derived: sum of 2 quarters · filed 2024-11-07 | -$51.14M 10-Q · filed 2024-11-07 | -$64.88M derived: sum of 4 quarters · filed 2024-11-07 | |||||||
| 2023-06-30 | -$17.83M 10-Q · filed 2024-08-13 | -$31.77M 10-Q · filed 2024-08-13 | -$45.52M derived: sum of 3 quarters · filed 2024-08-13 | -$58.23M derived: sum of 4 quarters · filed 2024-08-13 | |||||||
| 2023-03-31 | -$13.95M 10-Q · filed 2024-05-14 | -$27.69M derived: sum of 2 quarters · filed 2024-05-14 | -$40.40M derived: sum of 3 quarters · filed 2024-05-14 | -$52.37M derived: sum of 4 quarters · filed 2024-05-14 | |||||||
| 2022-12-31 | -$13.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$26.45M derived: sum of 2 quarters · filed 2024-03-05 | -$38.42M derived: sum of 3 quarters · filed 2024-03-05 | -$51.20M 10-K · filed 2024-03-05 | |||||||
| 2022-09-30 | -$12.71M 10-Q · filed 2023-11-09 | -$24.67M derived: sum of 2 quarters · filed 2023-11-09 | -$37.45M 10-Q · filed 2023-11-09 | -$49.53M derived: sum of 4 quarters · filed 2023-11-09 | |||||||
| 2022-06-30 | -$11.96M 10-Q · filed 2023-08-11 | -$24.74M 10-Q · filed 2023-08-11 | -$36.82M derived: sum of 3 quarters · filed 2023-08-11 | -$46.90M derived: sum of 4 quarters · filed 2023-08-11 | |||||||
| 2022-03-31 | -$12.78M 10-Q · filed 2023-05-12 | -$24.86M derived: sum of 2 quarters · filed 2023-05-12 | -$34.94M derived: sum of 3 quarters · filed 2023-05-12 | -$43.36M derived: sum of 4 quarters · filed 2023-05-12 | |||||||
| 2021-12-31 | -$12.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$22.16M derived: sum of 2 quarters · filed 2023-03-08 | -$30.58M derived: sum of 3 quarters · filed 2023-03-08 | -$36.83M 10-K · filed 2023-03-08 | |||||||
| 2021-09-30 | -$10.08M 10-Q · filed 2022-11-10 | -$18.50M derived: sum of 2 quarters · filed 2022-11-10 | -$24.75M 10-Q · filed 2022-11-10 | -$30.71M derived: sum of 4 quarters · filed 2022-11-10 | |||||||
| 2021-09-24 | $2.90M 10-K · filed 2024-03-05 | ||||||||||
| 2021-06-30 | -$8.42M 10-Q · filed 2022-08-12 | -$562.03K 10-Q · filed 2021-08-16 | -$14.67M 10-Q · filed 2022-08-12 | -$776.43K 10-Q · filed 2021-08-16 | -$20.63M derived: sum of 3 quarters · filed 2022-08-12 | -$26.64M derived: sum of 4 quarters · filed 2022-08-12 | |||||
| 2021-03-31 | -$6.25M 10-Q · filed 2022-05-12 | -$214.40K 10-Q · filed 2021-05-24 | -$12.21M derived: sum of 2 quarters · filed 2022-05-12 | -$18.22M derived: sum of 3 quarters · filed 2022-05-12 | -$18.55M derived: sum of 4 quarters · filed 2022-05-12 | ||||||
| 2020-12-31 | -$5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$11.97M derived: sum of 2 quarters · filed 2022-03-18 | -$12.29M derived: sum of 3 quarters · filed 2022-03-18 | -$20.68M 10-K · filed 2022-03-18 | -$935.40K 10-K · filed 2021-03-30 | ||||||
| 2020-09-30 | -$6.01M 10-Q · filed 2021-11-12 | -$220.29K 10-Q · filed 2020-11-10 | -$6.34M derived: sum of 2 quarters · filed 2021-11-12 | -$14.72M 10-Q · filed 2021-11-12 | -$776.52K 10-Q · filed 2020-11-10 | ||||||
| 2020-06-30 | -$327.56K 10-Q · filed 2021-08-16 | -$556.23K 10-Q · filed 2021-08-16 | |||||||||
| 2020-03-31 | -$228.67K 10-Q · filed 2021-05-24 | ||||||||||
| 2019-12-31 | -$136.30K 10-K/A · filed 2021-05-24 | ||||||||||
| 2019-11-21 | $2.90M 10-K · filed 2024-03-05 | ||||||||||
| 2019-08-30 | -$1.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |